News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
774,410 Results
Type
Article (53059)
Company Profile (296)
Press Release (721043)
Multimedia
Podcasts (153)
Webinars (24)
Section
Business (217047)
Career Advice (2583)
Deals (36777)
Drug Delivery (138)
Drug Development (85467)
Employer Resources (182)
FDA (17274)
Job Trends (15841)
News (366632)
Policy (35302)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2866)
Academic (1)
Accelerated approval (36)
Adcomms (31)
Allergies (158)
Alliances (53510)
ALS (183)
Alzheimer's disease (1768)
Antibody-drug conjugate (ADC) (342)
Approvals (17518)
Artificial intelligence (606)
Autoimmune disease (170)
Automation (44)
Bankruptcy (369)
Best Places to Work (12115)
BIOSECURE Act (22)
Biosimilars (202)
Biotechnology (189)
Bladder cancer (167)
Brain cancer (59)
Breast cancer (674)
Cancer (5124)
Cardiovascular disease (437)
Career advice (2186)
Career pathing (41)
CAR-T (297)
CDC (58)
Celiac Disease (2)
Cell therapy (806)
Cervical cancer (38)
Clinical research (72737)
Collaboration (1863)
Company closure (5)
Compensation (1205)
Complete response letters (65)
COVID-19 (2868)
CRISPR (101)
C-suite (922)
Cystic fibrosis (150)
Data (6518)
Decentralized trials (2)
Denatured (54)
Depression (144)
Diabetes (536)
Diagnostics (6993)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (47)
Drug discovery (291)
Drug pricing (207)
Drug shortages (33)
Duchenne muscular dystrophy (249)
Earnings (94385)
Editorial (67)
Employer branding (22)
Employer resources (161)
Events (125761)
Executive appointments (1047)
FDA (20543)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1569)
Gene editing (215)
Generative AI (60)
Gene therapy (664)
GLP-1 (1078)
Government (5098)
Grass and pollen (8)
Guidances (387)
Healthcare (20014)
HIV (65)
Huntington's disease (49)
IgA nephropathy (88)
Immunology and inflammation (276)
Immuno-oncology (69)
Indications (126)
Infectious disease (3167)
Inflammatory bowel disease (205)
Inflation Reduction Act (16)
Influenza (124)
Intellectual property (261)
Interviews (448)
IPO (16964)
IRA (56)
Job creations (4079)
Job search strategy (1812)
JPM (68)
Kidney cancer (17)
Labor market (88)
Layoffs (596)
Leadership (37)
Legal (8757)
Liver cancer (97)
Longevity (18)
Lung cancer (692)
Lymphoma (389)
Machine learning (43)
Management (63)
Manufacturing (857)
MASH (179)
Medical device (14339)
Medtech (14400)
Mergers & acquisitions (20921)
Metabolic disorders (1384)
mRNA (178)
Multiple sclerosis (172)
NASH (21)
Neurodegenerative disease (355)
Neuropsychiatric disorders (93)
Neuroscience (3104)
Neurotech (1)
NextGen: Class of 2026 (7038)
Non-profit (4901)
Now hiring (68)
Obesity (660)
Opinion (309)
Ovarian cancer (171)
Pain (213)
Pancreatic cancer (242)
Parkinson's disease (306)
Partnered (37)
Patents (527)
Patient recruitment (529)
Peanut (63)
People (62425)
Pharmaceutical (69)
Pharmacy benefit managers (33)
Phase 1 (22590)
Phase 2 (31850)
Phase 3 (23907)
Pipeline (5730)
Policy (327)
Postmarket research (2899)
Preclinical (9811)
Press Release (69)
Prostate cancer (264)
Psychedelics (51)
Radiopharmaceuticals (298)
Rare diseases (924)
Real estate (6396)
Recruiting (73)
Regulatory (26166)
Reports (54)
Research institute (2597)
Resumes & cover letters (418)
Rett syndrome (27)
RNA editing (19)
RSV (86)
Schizophrenia (160)
Series A (261)
Series B (197)
Service/supplier (13)
Sickle cell disease (106)
Special edition (25)
Spinal muscular atrophy (165)
Sponsored (46)
Startups (3843)
State (2)
Stomach cancer (20)
Supply chain (113)
Tariffs (87)
The Weekly (97)
Vaccines (1106)
Venture capital (98)
Weight loss (437)
Women's health (99)
Worklife (19)
Date
Today (250)
Last 7 days (823)
Last 30 days (2798)
Last 365 days (31477)
2026 (4681)
2025 (31679)
2024 (36474)
2023 (41296)
2022 (52552)
2021 (57261)
2020 (55986)
2019 (49115)
2018 (37173)
2017 (34072)
2016 (34132)
2015 (40119)
2014 (34329)
2013 (29829)
2012 (31762)
2011 (32184)
2010 (30740)
Location
Africa (917)
Alabama (89)
Alaska (7)
Arizona (322)
Arkansas (15)
Asia (43254)
Australia (7225)
California (11802)
Canada (3391)
China (1177)
Colorado (498)
Connecticut (515)
Delaware (347)
Europe (96657)
Florida (1752)
Georgia (375)
Hawaii (3)
Idaho (64)
Illinois (940)
India (73)
Indiana (550)
Iowa (23)
Japan (450)
Kansas (129)
Kentucky (43)
Louisiana (27)
Maine (75)
Maryland (1451)
Massachusetts (8542)
Michigan (345)
Minnesota (651)
Mississippi (6)
Missouri (142)
Montana (33)
Nebraska (29)
Nevada (126)
New Hampshire (86)
New Jersey (3174)
New Mexico (32)
New York (3113)
North Carolina (1563)
North Dakota (10)
Northern California (5765)
Ohio (355)
Oklahoma (23)
Oregon (44)
Pennsylvania (2373)
Puerto Rico (25)
Rhode Island (50)
South America (1304)
South Carolina (69)
South Dakota (1)
Southern California (4600)
Tennessee (183)
Texas (1824)
United States (42110)
Utah (355)
Vermont (1)
Virginia (283)
Washington D.C. (85)
Washington State (959)
West Virginia (4)
Wisconsin (131)
Wyoming (2)
774,410 Results for "w l gore and associates inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
W. L. Gore & Associates, Inc. Receives U.S. Food & Drug Administration (FDA) Approval for Lower Profile Gore® Viabahn® VBX Balloon Expandable Endoprosthesis, Now 6 FR Sheath Compatible
As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. announced recent FDA approval of a lower profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
January 31, 2024
·
4 min read
Press Releases
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
February 19, 2026
·
9 min read
GORE ANNOUNCES FIRST PATIENT IMPLANT IN THE ARISE II PIVOTAL STUDY OF THE GORE® ASCENDING STENT GRAFT
W. L. Gore & Associates (Gore) announced the first patient implantation of the GORE® Ascending Stent Graft in the ARISE II Trial, an exciting step in the development of treatments for pathologies involving the ascending aorta using endovascular repair rather than traditional open surgery.
December 20, 2023
·
3 min read
BioCapital
Gore PharmBIO Introduces 250mL, 500mL and 1L Protein Capture Devices With Protein A to Deliver Consistent Scalability and Increased Productivity Across Sizes
W. L. Gore & Associates, Inc. (“Gore”), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its 250mL, 500mL and 1L GORE® Protein Capture Devices with Protein A.
April 4, 2023
·
2 min read
BioMidwest
Gore Initiates Study to Compare the Gore® Viabahn® VBX Balloon Expandable Endoprosthesis to Bare Metal Stents
W. L. Gore & Associates announced the initiation of the Gore VBX FORWARD Clinical Study to compare the VBX Stent Graft to bare metal stenting for patients with complex iliac occlusive disease.
June 13, 2023
·
5 min read
Press Releases
Digital Disruption in Life Sciences: L7 Informatics Says Competitive Advantage Will Come From Governed Execution
L7 Informatics CEO explains why the next wave of life sciences innovation depends on digital unified platforms that orchestrate workflows, contextualize data, and enable AI-actionable operations.
February 12, 2026
·
1 min read
Business
Arzeda Announces Collaboration with W. L. Gore & Associates to Drive Innovation in Materials Research with Designer Proteins
Arzeda, the industry-leading Protein Design Company™, announced today that it is collaborating with W. L. Gore & Associates, a global leader in advanced materials science, on research leveraging Arzeda’s technology platform that economically and efficiently creates new and enhances existing proteins.
June 27, 2022
·
2 min read
Press Releases
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
January 21, 2026
·
10 min read
Gore announces first U.S. enrollment for the GORE® VIAFORT Vascular Stent iliofemoral Study
W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with five-year follow-up (NCT05489588) to evaluate the investigational GORE® VIAFORT Vascular Stent for the treatment of symptomatic iliofemoral venous obstruction.
June 6, 2023
·
2 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
1 of 77,441
Next
